Elísabeth Pérez-Ruiz

Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy

Elísabeth Pérez-Ruiz, Luna Minute, Itziar Otano et al. · Nature · 2019 · 486 citations · Full text

Life Sciences, Immunology, Oncology +17

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients

Niki Karachaliou, María González‐Cao, Guillermo Crespo et al. · Therapeutic Advances in Medical Oncology · 2018 · 274 citations · Full text

Medicine, Immunology, Oncology +17

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Laia Paré, Tomás Pascual, Elia Seguí et al. · Annals of Oncology · 2018 · 99 citations · Full text

Life Sciences, Immunology, Oncology +17

Combined oral cyclophosphamide and bevacizumab in heavily pre-treated ovarian cancer

Alfonso Sánchez, Bella Pajares, Elísabeth Pérez-Ruiz et al. · Clinical & Translational Oncology · 2008 · 65 citations

Medicine, Oncology, Pharmacology +14